Potential bias and mitigations when using stable isotope labeled parent drug as internal standard for LC-MS/MS quantitation of metabolites.
In recent years, increasing emphasis has been placed on quantitative characterization of drug metabolites for better insight into the correlation between metabolite exposure and toxicological observations or pharmacological efficacy. One common strategy for metabolite quantitation is to adopt the stable isotope labeled (STIL) parent drug as the internal standard in an isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. In the current work, we demonstrate this strategy could have a potential pitfall resulting in quantitation bias if the internal standard is subject to ion suppression from the co-eluting parent drug in the incurred samples. Propranolol and its metabolite 4-hydroxypropranolol were used as model compounds to demonstrate this phenomenon and to systematically evaluate different approaches to mitigate the issue, including atmospheric pressure chemical ionization (APCI) mode of ionization, increased internal standard concentration, quantitation without internal standard, the use of a structural analog as internal standard, and dilution of the samples. Case studies of metabolite quantitation in nonclinical and clinical studies in drug development were also included to demonstrate the importance of using an appropriate bioanalytical strategy for metabolite quantitation in the real world. We present that bias of metabolite concentrations could pose a potential for poor estimation of safety risk. A strategy for quantitation of metabolites in support of drug safety assessment is proposed.
Bioanalysis/DMPK, Johnson and Johnson Pharmaceutical Research and Development, 1000 Route 202 South, Raritan, NJ 08869, USA. wjian@its.jnj.com
Wenying
W
Jian
Richard W
RW
Edom
Yaodong
Y
Xu
Joseph
J
Gallagher
Naidong
N
Weng
D000818:Animals; D019540:Area Under Curve; D002853:Chromatography, Liquid / Q000379:methods* / Q000592:standards; D002986:Clinical Trials as Topic; D006801:Humans; D007553:Isotope Labeling / Q000379:methods*; D008956:Models, Chemical; D004364:Pharmaceutical Preparations / Q000032:analysis* / Q000097:blood / Q000378:metabolism / Q000652:urine; D011433:Propranolol / Q000031:analogs & derivatives / Q000032:analysis / Q000097:blood / Q000378:metabolism; D051381:Rats; D012015:Reference Standards; D012044:Regression Analysis; D053719:Tandem Mass Spectrometry / Q000379:methods* / Q000592:standards
D004364:Pharmaceutical Preparations; C001422:4-hydroxypropranolol; D011433:Propranolol